We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NGEN market cap is 137.09M. The company's latest EPS is CAD -0.3755 and P/E is -6.13.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.4M | -9.93M | -11.14M | -21.98M | -16.94M |
| Net Income | -9.77M | -11.19M | -12.73M | -20.72M | -22.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 6.77M | 6.68M | 17.9M | 23.88M | 13.24M |
| Total Liabilities | 924k | 755k | 1.08M | 10.41M | 15.25M |
| Total Equity | 5.84M | 5.92M | 16.82M | 13.46M | -2.01M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -8.09M | -6.31M | -8.27M | -17.78M | -11.3M |
| Investing | N/A | -3k | -44k | -21k | -139k |
| Financing | 9.84M | 7.85M | 19.61M | 22.64M | 766k |
| Market Cap | 137.09M |
| Price to Earnings Ratio | -6.13 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 11.76 |
| Price to Book Ratio | -68.24 |
| Dividend Yield | - |
| Shares Outstanding | 59.61M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.02 (0.87%) |
| Company Name | Nervgen Pharma Corporation |
| Address |
1133 melville street, suite 3500, the stack vancouver, british columbia V6E 4E5 |
| Website | https://nervgen.com/ |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
